SecBot SecBot
8-K ·Filed May 12, 2026

VTGN

Vistagen Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001628280-26-033883
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The OLE data is incrementally positive for safety but does not salvage the failed PALISADE-3 randomized trial. The stock's next catalyst is PALISADE-4 topline data in Q2 2026, a binary event that will determine whether fasedienol has a viable path to an NDA. Monitor for PALISADE-4 results and any financing needs given the small market cap.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.6200
T+0 close · May 12, 2026 · via day close
Latest settled
−54.23%
T+60 · $0.2838
Vs SPY
−58.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 12 $0.6200entry
  2. T+1 · 6mo ago +6.45%α +5.88% · $0.6600
  3. T+5 · 6mo ago −3.23%α −3.30% · $0.6000
  4. T+20 · 5mo ago −12.90%α −11.18% · $0.5400
  5. T+60 · 3mo ago −54.23%α −58.61% · $0.2838
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder. The OLE data showed fasedienol was well-tolerated over up to 12 months of as-needed use, with clinically relevant improvements on anxiety scales over four months. However, the randomized, placebo-controlled portion of PALISADE-3 failed its primary endpoint in December 2025, so this open-label data does not change the drug's regulatory path and the stock's binary risk profile remains tied to the upcoming PALISADE-4 topline results.

Key Facts

  • PALISADE-3 OLE safety data (n=341): fasedienol well-tolerated up to 12 months, 2.6% discontinuation rate due to AEs, no drug-related SAEs.
  • Exploratory efficacy: LSAS mean improvement of 25.4 points at Month 4 (n=228, 56% had ≥20-point improvement); SPIN mean improvement of 12.4 points at Month 4 (n=228, 55% had ≥10-point improvement).
  • The randomized, double-blind portion of PALISADE-3 failed its primary endpoint in December 2025, no treatment difference vs placebo on SUDS.
  • PALISADE-4 topline data expected in Q2 2026; Phase 2 Repeat Dose Study topline expected in Q3 2026.
  • Market cap is ~$27M with 0% analyst bullish consensus (7 Hold, 3 Sell/Strong Sell).

Financial Impact

No financial figures disclosed in filing. Company is pre-revenue clinical-stage biotech with $27M market cap.

Risk Factors

  • PALISADE-4 may also fail to meet its primary endpoint, mirroring PALISADE-3's failure.
  • Company may need to raise capital to fund ongoing operations, causing dilution.
  • Even if PALISADE-4 succeeds, FDA may require additional trials before accepting an NDA.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-033883
Document: vtgn-20260512.htm0001628280-26-033883
Document: 0001628280-26-033883-index-headers.html0001628280-26-033883
Document: 0001628280-26-033883-index.html0001628280-26-033883
Document: 0001628280-26-033883.txt0001628280-26-033883

Track record

21 reports on VTGN

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
  2. Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  4. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
  5. Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
  6. Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
  7. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
  8. Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  9. Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
  10. Aug 14, 202613w ago 8-K Bearish 6/10 No price data
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026